CONCLUSIONS : Current evidence supports the conclusion that the benefit of both anthracycline -based and taxane -based adjuvant chemotherapy is associated on HER2 /neu status , with patients with HER2 /neu -positive cancers benefiting more from these therapies than those with HER2 /neu -negative cancers .